FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON

HONG KONG

PARTNER OF MAIN
INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

STEVEN L. HIGHLANDER

TELEPHONE: 5

FACSIMILE: 51À

DIRECT DIAL: 512/536-3184

October 16, 2001

FILE: UTSC:618US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 16, 2001

Date

te len L. Highlander

Commissioner for Patents Washington, DC 20231

RE:

SN 09/899,807 "CANCER THERAPEUTICS INVOLVING THE ADMINISTRATION

OF 2-METHOXYESTRADIOL AND AN AGENT THAT INCREASES

INTRACELLULAR SUPEROXIDE ANION" - Peng Huang, et al. (Client Reference:

MDA99-031)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A20, C1-C31).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10105829/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven Highlander

Reg. No. 37,642

SLH/cmb

Encl: as noted

25075660.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peng Huang, et al.

Serial No.: 09/899,807

Filed: July 5, 2001

For: CANCER THERAPEUTICS INVOLVING

THE ADMINISTRATION OF 2-METHOXYESTRADIOL AND AN AGENT THAT INCREASES

INTRACELLULAR SUPEROXIDE

ANION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:618US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 2003 non the date below:

October 16, 2001

Date

teven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10105829/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

October 16, 2001